Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-06
2005-12-06
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S394000, C514S395000, C546S118000
Reexamination Certificate
active
06972293
ABSTRACT:
Disclosed are compounds of the formula:or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
REFERENCES:
patent: 3255202 (1966-06-01), Johnson
patent: 3455940 (1969-07-01), Stecker
patent: 3905990 (1975-09-01), Ehrmann et al.
patent: 3941788 (1976-03-01), Hankovszky et al.
patent: 3995044 (1976-11-01), Kabbe et al.
patent: 5066576 (1991-11-01), Ichijima et al.
patent: 5296339 (1994-03-01), Fujita et al.
patent: 5789428 (1998-08-01), Shibata et al.
patent: 5877195 (1999-03-01), Lunkenheimer et al.
patent: 6380210 (2002-04-01), DeSimone et al.
patent: 0 598 962 (1994-06-01), None
patent: 0 616 807 (1994-09-01), None
patent: 0 882 718 (1998-12-01), None
patent: 1 501 151 (1966-10-01), None
patent: 7-133224 (1995-05-01), None
patent: WO 96/00730 (1996-01-01), None
patent: WO 96/33191 (1996-10-01), None
patent: WO 98/33194 (1996-10-01), None
patent: WO 96/39404 (1996-12-01), None
patent: WO 97/24119 (1997-07-01), None
patent: WO 98/17651 (1998-04-01), None
patent: WO 96/45295 (1998-10-01), None
patent: WO 99/37303 (1999-07-01), None
patent: WO 99/47131 (1999-09-01), None
patent: WO 99/47142 (1999-09-01), None
patent: WO 99/47171 (1999-09-01), None
Aryuzina et al., “Synthesis of 4H-Imidazol[5,1-a]Benzimidazole Sustituents, VIII*, Synthesis of 1-Phenyl-4-Benzylimidazo[5,1-a]Benzimidazole and Some of Its 3-Substituents”,Chemistry of Heterocyclic Compounds, No. 3, 1973, pp. 395-397.
Aryuzina et al., “The Synthesis of Substitution Products of 4H-Imidazo[5,1-b]Benzimidazole, V*, Some Substitution Reactions of 1,4,-Dimethyl and 1-Phenyl-4-Methylimidazo[5,1-b]Benzimidazoles”,Chemistry of Heterocyclic Compounds, 1970, vol. 4, pp. 526-528.
Chemical Abstracts, vol. 127, No. 3, abstract No. 34242m, column 650. (Jul. 21, 1997).
Chemical Abstracts, vol. 73, No. 17, abstract No. 87845h. (Oct. 26, 1970).
Cooper, et al.,The Biochemical Basis of Neuropharmacology, 6thed., (1991) pp. 145-148.
Christos T.E. et al., “Corticotrophin-releasing factor receptor antagonists”, Expert Opinion on Therapeutic Patents, vol. 8, No. 2, Feb. 1998, pp. 143-152, XP002109498.
Da-Rocha, et al.,Psychopharmacology(1997) 11(3): pp. 211-218.
Knight et al.,Receptors Channels(1998); 6: pp. 1-18.
Kuhnz and Gieschen,Drug Metabolism and Disposition(1998) 26: pp. 1120-1127.
Le, et al.,Alcohol and Alcoholism(1996) 31 Suppl. pp. 127-132.
Mohler et al.,Neurach. Res.(1995); 20(5): pp. 631-636.
Oravocva, et al.,Journal of Chromatography B(1996) 677: pp. 1-27.
Pritchett & Seeburg,Science(1989) 245: pp. 1389-1392.
Smith, et al.,Am. J. Psychiatry(1998) 155(10): pp. 1339-1345.
Thomas and Tallman,J. Bio. Chem.(1981) 156; 9838-9842.
Thomas and Tallman,J. Neurosci.(1983) 3: pp. 433-440.
White and Gurley,NeuroReport(1995) 6: pp. 1313-1316.
White, et al.,Receptors and Channels(1995) 3: pp. 1-5.
GenBank Accession No. X14766.
GenBank Accession No. A28100.
GenBank Accession No. A28102.
GenBank Accession No. A28104.
GenBank Accession No. M82919.
GenBank Accession No. Z20136.
GenBank Accession No. X15376.
GenBank Accession No. L08490.
GenBank Accession No. L08491.
GenBank Accession No. L08492.
GenBank Accession No. L08494.
GenBank Accession No. X15467.
GenBank Accession No. X15468.
GenBank Accession No. L08497.
DeSimone Robert W.
Hutchison Alan
Rosewater Daniel L.
Shaw Kenneth
McDonnell Boehnen & Hulbert & Berghoff LLP
Neurogen Corporation
Seaman D. Margaret
LandOfFree
Heteroaryl fused aminoalkyl-imidazole derivatives: selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl fused aminoalkyl-imidazole derivatives: selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl fused aminoalkyl-imidazole derivatives: selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3508402